AstraZeneca PLC
Financial Performance
AstraZeneca Revenue & Financials
Revenue
$58.7B (FY2025)
Market Cap
$254.6B
Net Income
$10.2B
Employees
96,100
What is AstraZeneca's revenue?
AstraZeneca had $58.7B in revenue for fiscal year 2025, up 8.6% from 2024. Net income was $10.2B.
- Latest revenue
- $58.7B (FY2025)
- Year-over-year
- +8.6%
- Growth rate (CAGR)
- 11% over 9 years
- Peak revenue
- $58.7B (FY2025)
- Years of data
- 10
- Employees
- 96,100
- How much profit does AstraZeneca make?
- AstraZeneca reported net income of $10.2B for fiscal year 2025. sec.gov
- How many employees does AstraZeneca have?
- AstraZeneca has about 96,100 employees.
Financial Analysis
AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021. AstraZeneca is a massive global biopharmaceutical company, sustaining a market valuation often exceeding $200 billion.
Revenue Trend Analysis
YoY Change
+8.6%
9-Year CAGR
+11%
Peak Year
2025
Trend
Consistent Growth
AstraZeneca PLC has 10 full fiscal year figures on this page, compounding at +11% annually over 9 years. The most recent year saw a 8.6% increase versus the prior year. Annual revenue peaked in fiscal year 2025 at $58.7B. Of 9 comparable year-over-year steps, 7 showed growth and 2 showed a decline.
Annual revenue history
| Fiscal Year | Revenue | Net Income | YoY Change | Source |
|---|---|---|---|---|
| FY2025 | $58.7B | $10.2B | +8.6% | SEC 20-F Total Revenue of $58,739m: Product Sales $55,573m, Alliance Revenue $3,067m, Collaboration Revenue $99m. Up 8% at constant exchange rates. |
| FY2024 | $54.1B | $7B | +18.0% | Annual report 2024 An 18% rise at actual rates on oncology, cardiovascular and Alexion rare-disease sales. |
| FY2023 | $45.8B | $6B | +3.3% | Annual report 2023 The $45 billion revenue level Pascal Soriot promised investors for 2023 when the board rejected Pfizer in 2014. |
| FY2022 | $44.4B | $3.3B | +18.5% | SEC 20-F First full year with Alexion consolidated for the whole period. |
| FY2021 | $37.4B | $115M | +40.6% | SEC 20-F Alexion consolidated from July 2021; profit reduced by acquisition and COVID-19 vaccine costs. |
| FY2020 | $26.6B | $3.1B | +9.2% | SEC 20-F Growth led by oncology and new CVRM medicines during the first pandemic year. |
| FY2019 | $24.4B | $1.2B | +10.4% | SEC 20-F Return to growth as Tagrisso, Imfinzi and Farxiga scaled. |
| FY2018 | $22.1B | $2B | -1.7% | SEC 20-F (XBRL) The low point of the patent-cliff decade. |
| FY2017 | $22.5B | $2.9B | -2.3% | SEC 20-F (XBRL) Revenue still falling as Crestor and Seroquel XR generics spread. |
| FY2016 | $23B | $3.4B | — | SEC 20-F (XBRL) Down 7% at actual rates; US Crestor sales fell 57% to $1,223m on generic entry. |
Click any row to see year details.
AstraZeneca PLC balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 20-F, linked on each row. Free cash flow here is operating cash flow less capital expenditures, calculated by CorpDigest. In some years total assets exceed liabilities plus shareholders' equity because the company reported redeemable preferred stock or non-controlling interests outside both.
| Fiscal Year | Operating cash flow | Capital expenditures | Total assets | Total liabilities | Shareholders' equity | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $14.6B | $2.8B | $114.1B | $65.4B | $48.7B | $11.8B | Form 20-F |
| FY2024ended Dec 31, 2024 | $11.9B | $1.9B | $104B | $63.2B | $40.8B | $9.9B | Form 20-F |
| FY2023ended Dec 31, 2023 | $10.3B | $1.4B | $101.1B | $62B | $39.1B | $9B | Form 20-F |
| FY2022ended Dec 31, 2022 | $9.8B | $1.1B | $96.5B | $59.4B | $37B | $8.7B | Form 20-F |
| FY2021ended Dec 31, 2021 | $6B | $1.1B | $105.4B | $66.1B | $39.3B | $4.9B | Form 20-F |
| FY2020ended Dec 31, 2020 | $4.8B | $961M | $66.7B | $51.1B | $15.6B | $3.8B | Form 20-F |
| FY2019ended Dec 31, 2019 | $3B | $979M | $61.4B | $46.8B | $13.1B | $2B | Form 20-F |
| FY2018ended Dec 31, 2018 | $2.6B | $1B | $60.7B | $46.6B | $12.5B | $1.6B | Form 20-F |
| FY2017ended Dec 31, 2017 | $3.6B | $1.3B | $63.4B | $46.7B | $15B | $2.3B | Form 20-F |
| FY2016ended Dec 31, 2016 | $4.1B | $1.4B | $62.5B | $45.9B | $14.9B | $2.7B | Form 20-F |
Related Companies
Compare AstraZeneca PLC Revenue With Competitors
Keep researching AstraZeneca
AstraZeneca Revenue and Financial FAQ
What is AstraZeneca's annual consolidated revenue scale?
AstraZeneca PLC reported revenue of $58.7 billion for fiscal year 2025, up from $54.1 billion in fiscal 2024.
How is AstraZeneca's revenue distributed across its core disease areas?
Oncology was the largest therapy area in 2025 at roughly $25.6 billion, about 44% of product revenue, followed by Cardiovascular, Renal and Metabolism at around 22%. Respiratory and Immunology and Rare Disease account for most of the remainder, with Vaccines and Immune Therapies smaller again.
How much capital does AstraZeneca invest annually in Research and Development (R&D)?
AstraZeneca invested $14.2 billion in research and development in 2025, up 4% on 2024 and about a quarter of Total Revenue, one of the highest R&D intensities among large-cap pharmaceutical companies.
What is AstraZeneca's operating profit margin and core EPS performance?
AstraZeneca achieves Core Operating Margins typically between 31% and 34%, expanding operating leverage through high gross margins (>80% on proprietary specialty biologics) and global sales force efficiency.
What is AstraZeneca's corporate debt profile following the Alexion acquisition?
AstraZeneca funded the $39 billion Alexion acquisition in 2021 with cash and newly issued shares rather than debt alone, and has reduced leverage since while keeping investment-grade ratings. Gross profit of $48.1 billion on Total Revenue of $58.7 billion in 2025 covers debt service, a full-year dividend of $3.20 per share and the $50 billion US investment programme.
What dividend policy does AstraZeneca maintain for shareholders?
AstraZeneca maintains a progressive dividend policy, paying semi-annual cash dividends that have grown consistently, targeting a dividend payout ratio of approximately 45 to 50% of Core EPS.
What is AstraZeneca's revenue distribution across geographical markets?
The United States represents approximately 40 to 43% of total revenue, followed by Emerging Markets (~25 to 28%, including China as a major market), Europe (~20 to 22%), and the Rest of the World (Japan/AP).
What credit ratings do S&P and Moody's assign to AstraZeneca?
AstraZeneca holds investment-grade credit ratings in the single-A range from S&P Global Ratings and Moody's Ratings, supported by portfolio diversity across four therapy areas and consistent operating cash flow.
Is AstraZeneca profitable?
Yes, AstraZeneca is highly profitable, generating massive free cash flow from its portfolio of blockbuster cancer drugs like Tagrisso and Imfinzi.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "AstraZeneca Revenue & Financials." CorpDigest, https://corpdigest.com/company/astrazeneca/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>AstraZeneca reported $58.7B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/astrazeneca/financials" target="_blank" rel="noopener">CorpDigest — AstraZeneca financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore AstraZeneca
Core profile pages, founders and related research hubs for this company.